ALT — Altimmune, Inc.
Is ALT overbought or oversold? Here is the current MarketMoodz read.
Altimmune, Inc. (ALT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.56. The rating moved from Oversold to Strong Oversold on November 13, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.56
- Last changeMoved from Oversold to Strong Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Altimmune, Inc. (ALT) is a small‑cap biotech with typical binary upside tied to clinical/regulatory events and downside tied to cash runway and potential dilution. The broader market tone is cautiously optimistic, but flows currently favor large‑cap pharma and defensive names rather than speculative mid/small‑cap biotech. Without clear near‑term positive catalysts or visible non‑dilutive financing, valuation and liquidity risks remain elevated. Monitor upcoming company disclosures, cash runway metrics, and any financing activity closely.
Key factors
- Small‑cap biotech profile with binary clinical and regulatory catalysts that can drive large short‑term moves
- Limited public financial transparency in the provided dataset; typical cash/runway sensitivity for sub-$5 names
- Sector environment favoring large-cap pharma as defensive allocation, which can starve mid/small-cap biotechs of flows
- Potential near‑term catalysts (clinical readouts, partner/licensing announcements) could provide upside if positive
- Convertible‑debt/dilution theme in the sector increases the chance of shareholder dilution or hedging pressure
- Low liquidity and retail-driven volatility common for low‑priced tickers, increasing price dispersion around news
Risks
- Clinical trial failure or negative readout for lead programs leading to severe de‑rating
- Short cash runway requiring dilutive financing (equity offerings or convertibles) that would depress share value
- Regulatory setbacks or slower than expected approvals/commercialization timelines
- Competitive threats from larger pharma/biotech with deeper pockets and established commercial channels
- Low analyst coverage and thin liquidity increasing price volatility and making exits difficult for holders
- Macro/sector rotation into large-cap defensive pharma could reduce available capital for small biotechs
See today's live rating, score and targets
Members see the live hourly rating for ALT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.